Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 22;24(1):169.
doi: 10.3390/ijms24010169.

Hand-Foot-and-Mouth Disease-Associated Enterovirus and the Development of Multivalent HFMD Vaccines

Affiliations
Review

Hand-Foot-and-Mouth Disease-Associated Enterovirus and the Development of Multivalent HFMD Vaccines

Xinglong Zhang et al. Int J Mol Sci. .

Abstract

Hand-foot-and-mouth disease (HFMD) is an infectious disease of children caused by more than 20 types of enteroviruses, with most cases recovering spontaneously within approximately one week. Severe HFMD in individual children develops rapidly, leading to death, and is associated with other complications such as viral myocarditis and type I diabetes mellitus. The approval and marketing of three inactivated EV-A71 vaccines in China in 2016 have provided a powerful tool to curb the HFMD epidemic but are limited in cross-protecting against other HFMD-associated enteroviruses. This review focuses on the epidemiological analysis of HFMD-associated enteroviruses since the inactivated EV-A71 vaccine has been marketed, collates the progress in the development of multivalent enteroviruses vaccines in different technical routes reported in recent studies, and discusses issues that need to be investigated for safe and effective HFMD multivalent vaccines.

Keywords: HFMD; multivalent vaccines; systemic immunity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The epidemiological data of HFMD. (a) The number of HFMD cases in China from 2008 to 2021 and the ranking of its morbidity among C infectious diseases. The data in the figure are cited from www.chinacdc.cn (accessed on 10 October 2022). (b) The fatality rate of HFMD in China from 2008 to 2021 and its ranking among category C infectious diseases. The data in the figure are cited from www.chinacdc.cn (accessed on 10 October 2022). (c) The rate of severe HFMD illnesses before and after the first inactivated EV-A71 vaccine was approved in China. The data in the figure are cited from [23]. (d) Seropositivity rates of different HFMD-associated enteroviruses in Vietnam and Korea. The data in the figure are cited from [24,25].
Figure 2
Figure 2
Seropositivity rates of different HFMD-associated enteroviruses in the whole of China along with the Chengdu and Kunming areas, 2013–2020. (a) Seropositivity rates of different HFMD-associated enteroviruses in the whole of China, 2013–2019. The data in the figure are cited from [26]. (b) Seropositivity rates of different HFMD-associated enteroviruses in Chengdu, Sichuan province, China. The data in the figure are cited from [27]. (c) Seropositivity rate of different HFMD-associated enteroviruses before EV-A71 inactivated vaccine vaccination in Kunming, Yunnan Province, China. The data in the figure are cited from [28]. (d) Seropositivity rate of different HFMD-associated enteroviruses after EV-A71 inactivated vaccine in Kunming, Yunnan Province, China. The data in the figure are cited from [29].
Figure 3
Figure 3
The potential mechanism that intradermal immunization is more effective than intramuscular immunization. Image created with BioRender (https://biorender.com/, accessed on 10 October 2022).
Figure 4
Figure 4
A series of potential methods to get more balanced immune responses and a broader spectrum of protective immune responses in development of multivalent HFMD vaccines. Image created with BioRender (https://biorender.com/, accessed on 10 October 2022).

Similar articles

Cited by

References

    1. Ang P.Y., Chong C.W.H., Alonso S. Viral determinants that drive Enterovirus-A71 fitness and virulence. Emerg. Microbes Infect. 2021;10:713–724. doi: 10.1080/22221751.2021.1906754. - DOI - PMC - PubMed
    1. Kobayashi K., Koike S. Adaptation and Virulence of Enterovirus-A71. Viruses. 2021;13:1661. doi: 10.3390/v13081661. - DOI - PMC - PubMed
    1. Martínez-Salas E., Francisco-Velilla R., Fernandez-Chamorro J., Lozano G., Diaz-Toledano R. Picornavirus IRES elements: RNA structure and host protein interactions. Virus Res. 2015;206:62–73. doi: 10.1016/j.virusres.2015.01.012. - DOI - PubMed
    1. Fernández-Miragall O., de Quinto S.L., Martínez-Salas E. Relevance of RNA structure for the activity of picornavirus IRES elements. Virus Res. 2009;139:172–182. doi: 10.1016/j.virusres.2008.07.009. - DOI - PubMed
    1. Jang S.K., Pestova T.V., Hellen C.U., Witherell G.W., Wimmer E. Cap-independent translation of picornavirus RNAs: Structure and function of the internal ribosomal entry site. Enzyme. 1990;44:292–309. doi: 10.1159/000468766. - DOI - PubMed

LinkOut - more resources